Ever-widening knowledge base proves that there's more to it than controlling IOPs.
Internal limiting membrane staining dye ILM-Blue (DORC) receives NMPA approval in China
The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss
Higher Molar Dose and Its Translation into Clinical Practice
Nanoscope Therapeutics publishes clinical results of MCO-010 findings for patients with retinitis pigmentosa
The synthetic opsin was packaged into an optimised AAV2 gene therapy vector that targets human retinal bipolar cells.
Alcon Clareon Vivity IOL receives CE mark, European commercialisation announced
The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3
Moorfields Eye Hospital INSIGHT research hub will collaborate with artificial intelligence development company Insitro
The partnership will use ocular imaging to build an AI foundation model and identify new genetic targets for degenerative diseases
Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports
The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration
